Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Full Paper
  • Published:

Evidence of a pharmacogenomic response to interleukin-l receptor antagonist in rheumatoid arthritis

Genes & Immunity volume 6, pages 467–471 (2005)Cite this article

Abstract

Biological activity of the IL-1 system depends on the balance between two proinflammatory proteins (IL-1α and IL-1β) and the related anti-inflammatory protein, the IL-1 receptor antagonist (IL-1Ra). The genes for these proteins lie within 430 kb on human chromosome 2. Based on a clinical trial of human recombinant IL-1ra in rheumatoid arthritis, we tested whether IL-1 genotype might be related to the likelihood of response to anti-IL-1 therapy. A positive response was defined as a reduction of at least 50% in the number of swollen joints by week 24, following treatment with either 150 mg/day IL-1ra or placebo. The response rate to treatment, independent of genotype, was 48% (44/91). A highly significant association was found between carriage of the rarer allele at IL1A(+4845) and response to treatment (P=0.0009; OR=4.85 (1.85,12.70)). The response rate in patients carrying this allele was 63.4% compared with 26.3% in noncarriers. A weaker association was found for IL1B(+3954) (P=0.02). There was a highly significant interaction between treatment (150 mg/day or placebo) and the composite genotype across IL1A(+4845) and IL1B(+3954) (P=7.6 × 10−5). No associations with IL-1 genotypes were found in patients receiving placebo. Thus, a significant pharmacogenomic effect was found in the treatment of RA patients with recombinant IL-1ra.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Choy EH, Panayi GS . Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001; 22: 907–916.

    Article  Google Scholar 

  2. di Giovine FS, Nuki G, Duff GW . Tumour necrosis factor in synovial exudates. Ann Rheum Dis 1988; 47: 768–772.

    Article  CAS  Google Scholar 

  3. Eastgate JA, Symons JA, Wood NC, Grinlinton FM, di Giovine FS, Duff GW . Correlation of plasma interleukin-1 levels with disease activity in rheumatoid arthritis. Lancet 1988; 8613: 706–709.

    Article  Google Scholar 

  4. Brennan F, Jackson A, Chantry D, Maini R, Feldmann M . Inhibitory effect of TNF-alpha antibodies on synovial cell interleukin-1 production in rheumatoid-arthritis. Lancet 1989; 8657: 244–247.

    Article  Google Scholar 

  5. Dinarello CA . Biologic basis for interleukin-1 in disease. Blood 1996; 87: 2095–2147.

    CAS  Google Scholar 

  6. Horai R, Saijo S, Tanioka H et al. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin-1 receptor antagonist-deficient mice. J Exp Med 2000; 191: 313–320.

    Article  CAS  Google Scholar 

  7. Joosten LA, Helsen MMA, van de Loo FAJ, van den Berg WB . Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNFα, anti-IL-1α/β, and IL-1ra. Arthr Rheum 1996; 39: 797–809.

    Article  CAS  Google Scholar 

  8. Bendele A, McAbee T, Sennello G, Frazier J, Chlipala E, McCabe D . Efficacy of sustained blood levels of interleukin-1 receptor antagonist in animal models of arthritis. Arth Rheum 1999; 42: 498–506.

    Article  CAS  Google Scholar 

  9. Bresnihan B, Alvaro-Gracia JM, Cobby M et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthr Rheum 1998; 41: 2196–2204.

    Article  CAS  Google Scholar 

  10. Nicklin MJH, Weith A, Duff GW . A physical map of the region encompassing the human interleukin-1 alpha, beta and the interleukin-1 receptor antagonist genes. Genomics 1994; 19: 382–384.

    Article  CAS  Google Scholar 

  11. Nothwang HG, Strahm B, Denich D et al. Molecular cloning of the interleukin-1 gene cluster: construction of an integrated YAC/PAC contig and partial transcriptional map in the region of chromosome 2q13. Genomics 1997; 41: 370–378.

    Article  CAS  Google Scholar 

  12. Cox A, Camp NJ, Nicklin MJH, di Giovine FS, Duff GW . An analysis of linkage disequilibrium in the interleukin-1 gene cluster, using a novel grouping method for multiallelic markers. Am J Hum Genet 1998; 62: 1180–1188.

    Article  CAS  Google Scholar 

  13. Pociot F, Molvig J, Wogensen L, Worsae H, Nerup J . A TaqI polymorphism in the human interleukin-1 beta (IL-1beta) gene correlates with IL-1 beta secretion in vitro. Eur J Clin Invest 1992; 22: 396–402.

    Article  CAS  Google Scholar 

  14. Cox A, Camp NJ, Cannings C et al. Combined sib-TDT and TDT provide evidence for linkage of the interleukin-1 gene cluster to erosive rheumatoid arthritis. Hum Mol Genet 1999; 8: 1707–1713.

    Article  CAS  Google Scholar 

  15. Cantagrel A, Navaux F, Loubet-Lescoulie P et al. Interleukin-1β, interleukin-1 receptor antagonist, interleukin-4, and interleukin-10 gene polymorphisms. Relationship to occurrence and severity of rheumatoid arthritis. Arthr Rheum 1999; 42: 1093–1100.

    Article  CAS  Google Scholar 

  16. Jouvenne P, Chaudhary A, Buchs N, di Giovine FS, Duff GW, Miossec P . Possible genetic association between interleukin-1 alpha gene polymorphism and the severity of chronic polyarthritis. Eur Cytokine Network 1999; 10: 33–36.

    CAS  Google Scholar 

  17. Elliott M, Maini R, Feldmann M et al. Treatment of rheumatoid-arthritis with chimeric monoclonal-antibodies to tumor-necrosis-factor-alpha. Arthr Rheum 1993; 36: 1681–1690.

    Article  CAS  Google Scholar 

  18. Nicoll JA, Mrak RE, Graham DI et al. Association of interleukin-1 gene polymorphisms with Alzheimer's disease. Ann Neurol 2000; 47: 365–368.

    Article  CAS  Google Scholar 

  19. Kornman KS, Crane A, Wang H-Y et al. The interleukin-1 genotype as a severity factor in adult periodontal disease. J Clin Periodontol 1997; 24: 72–77.

    Article  CAS  Google Scholar 

  20. Hulkkonen J, Laippala P, Hurme M . A rare allele combination of the interleukin-1 gene complex is associated with high interleukin-1 beta plasma levels in healthy individuals. Eur Cytokine Network 2000; 11: 251–255.

    CAS  Google Scholar 

  21. Hernandez-Guerrero C, Monzon-Bordonaba F, Jimenez-Zamudio L et al. In-vitro secretion of proinflammatory cytokines by human amniochorion carrying hyper-responsive gene polymorphisms of tumour necrosis factor-alpha and interleukin-1beta. Mol Hum Reprod 2000; 9: 625–629.

    Article  Google Scholar 

  22. Santtila S, Savinainen K, Hurme M . Presence of the IL-1RA allele 2 (ILRN*2) is associated with enhanced IL-1β production in vitro. Scand J Immunol 1998; 47: 195–198.

    Article  CAS  Google Scholar 

  23. Danis VA, Millington M, Hyland VJ, Grennan D . Cytokine production by normal human monocytes: inter-subject variation and relationship to an IL-1 receptor antagonist (IL-1Ra) gene polymorphism. Clin Exp Immunol 1995; 99: 303–310.

    Article  CAS  Google Scholar 

  24. Buch MH, Bingham SJ, Seto Y et al. Lack of response to Anakinra in rheumatoid arthritis following failure of tumour necrosis factor α blockade. Arthr Rheum 2004; 50: 725–728.

    Article  CAS  Google Scholar 

  25. Saxne T, Larsson L, Geborek P . Results of anakinra treatment in rheumatoid arthritis patients previously treated with tumour necrosis factor α blockade: comment on the article by Buch et al. Arthr Rheum 2004; 50: 3049–3051.

    Article  Google Scholar 

  26. Schiff MH . Lack of response to anakinra in rheumatoid arthritis following failure of tumour necrosis factor α blockade: comment on the article by Buch et al. Arthr Rheum 2005; 52: 364–365.

    Article  Google Scholar 

  27. Roses AD . Genome-based pharmacogenetics and the pharmaceutical industry. Nat Rev Drug Discov 2002; 1: 541–549.

    Article  CAS  Google Scholar 

  28. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS . The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthr Rheum 1988; 31: 315–324.

    Article  CAS  Google Scholar 

  29. di Giovine FS, Camp NJ, Cox A et al. Detection and population analysis of IL-1 and TNF gene polymorphisms. In: Balkwill F (ed) Cytokine Molecular Biology. Oxford University Press: Oxford, 2000, pp 21–46.

    Google Scholar 

Download references

Acknowledgements

DM and WR are employed by Amgen Inc. and the research was funded by Amgen Inc. NJC and AC were supported by a grant from the Arthritis and Rheumatism Campaign.

Author information

Author notes

  1. N J Camp

    Present address: Department of Medical Informatics, University of Utah, Salt Lake City, UT, USA

Authors and Affiliations

  1. Division of Genomic Medicine, University of Sheffield, UK

    N J Camp, A Cox, F S di Giovine & G W Duff

  2. Amgen Inc., CA, USA

    D McCabe & W Rich

Authors
  1. N J Camp
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A Cox
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F S di Giovine
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D McCabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. W Rich
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G W Duff
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A Cox.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Camp, N., Cox, A., di Giovine, F. et al. Evidence of a pharmacogenomic response to interleukin-l receptor antagonist in rheumatoid arthritis. Genes Immun 6, 467–471 (2005). https://doi.org/10.1038/sj.gene.6364228

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.gene.6364228

Keywords

This article is cited by

Search

Advanced search

Quick links